Berinert FDA Approval History
FDA Approved: Yes (First approved October 9, 2009)
Brand name: Berinert
Generic name: C1 esterase inhibitor (human)
Dosage form: Injection
Company: CSL Behring
Treatment for: Angioedema
Berinert (C1-esterase inhibitor (human)) is a plasma derived C1 esterase inhibitor indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adult and adolescent patients.
Development Timeline for Berinert
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.